mortality/aging
• mice show decreased overall survival, with a mean life span of 75 weeks
|
endocrine/exocrine glands
• mice develop prostatic adenocarcinoma by 10 weeks of age
• mice with developed tumors treated with a small-molecule inhibitor of P-eIF2alpha activity, ISRIB, show tumor regression within 3 weeks of treatment, with no signs of toxicity
|
• mice show enlargement of prostate growth by 6 weeks of age and accelerated development of high-grade prostatic intraepithelial neoplasia compared to single conditional Ptentm1Hwu mutants
|
neoplasm
• mice develop prostatic adenocarcinoma by 10 weeks of age
• mice with developed tumors treated with a small-molecule inhibitor of P-eIF2alpha activity, ISRIB, show tumor regression within 3 weeks of treatment, with no signs of toxicity
|
• mice show enlargement of prostate growth by 6 weeks of age and accelerated development of high-grade prostatic intraepithelial neoplasia compared to single conditional Ptentm1Hwu mutants
|
reproductive system
• mice develop prostatic adenocarcinoma by 10 weeks of age
• mice with developed tumors treated with a small-molecule inhibitor of P-eIF2alpha activity, ISRIB, show tumor regression within 3 weeks of treatment, with no signs of toxicity
|
• mice show enlargement of prostate growth by 6 weeks of age and accelerated development of high-grade prostatic intraepithelial neoplasia compared to single conditional Ptentm1Hwu mutants
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:261540 |